Overall, our study identifies SIN3B as a potential therapeutic target for improving cytotoxic T cell accessibility to the tumor microenvironment and enhancing immunotherapy efficacy in the challenging context of PDAC. This evidence concerns the gene SIN3B and neoplasm.